GlassScriptPhysician profile
Joseph A Solomito
NPI 1407887078
$1,372.74
in general payments reported to CMS, 2019-2025
13 companies · $51.65 in 2025
The $51.65 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $204 · 2021: $380 · 2022: $125 · 2024: $110 · 2025: $51.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $263.67 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.87 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $177.42 | 2019-2024 | Watchman Access System |
| Esperion Therapeutics, INC. | $131.71 | 2021-2024 | Nexletol |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $99.87 | 2021 | |
| United Therapeutics Corporation | $78.18 | 2021-2025 | Orenitram |
| Pfizer INC. | $77.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.91 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $33.36 | 2024-2025 | Winrevair |
| Bard Peripheral Vascular, INC. | $16.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Solomito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.